Business Context and Reporting Period
This Form 8-K Current Report was filed by Longeveron Inc. (NASDAQ: LGVN) on August 27, 2025, with the earliest event reported on the same date. The filing addresses significant changes in executive leadership and board composition.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and personnel changes.
Material Changes
- CEO Departure: Wa'el Hashad stepped down as Chief Executive Officer and Board member effective immediately on August 27, 2025, to pursue other opportunities.
- Interim CEO Appointment: Than Powell, currently the Chief Business Officer, was appointed Interim Chief Executive Officer, effective September 4, 2025.
- Board Restructuring: Dr. Joshua Hare, the Company's founder and Chief Science Officer, was appointed Executive Chairman of the Board.
Management Commentary and Compensation
Mr. Powell brings over 25 years of pharmaceutical and biotech leadership experience, including roles at GSK, Eli Lilly, and Surescripts. As Interim CEO, his compensation package includes:
- Base salary of $500,000.
- Potential prorated target bonus payments at 60% of base salary.
- An equity grant consisting of restricted stock units and stock options, subject to vesting.
The Board confirmed there are no undisclosed arrangements regarding Mr. Powell's selection.
Investor Verification Checklist
- Verify the effective date of Than Powell's interim CEO role (September 4, 2025).
- Review the attached Press Release (Exhibit 99.1) for additional strategic context regarding the leadership transition.
- Monitor future filings for the timeline and criteria for selecting a permanent CEO successor.
- Confirm the specific vesting terms of the equity grant awarded to Mr. Powell in subsequent filings.